Efficacy of COVID-19 vaccines: a systematic review and network meta-analysis of phase 3 randomized controlled trials

Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts. J Med Virol. 2022;94:1294–9. https://doi.org/10.1002/jmv.27463.

Chen JM. Should the world collaborate imminently to develop neglected live-attenuated vaccines for COVID-19? J Med Virol. 2022;94:82–7.

WHO Coronavirus (COVID-19) Dashboard [Internet]. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. covid19.who.int; [cited 2022 Mar 10]. Available from: https://covid19.who.int/.

Kumar S, Saurabh MK, Maharshi V. Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: a systematic review. J Adv Pharm Technol Res. 2021;12:215–21.

Kumar S, Saurabh MK, Maharshi V, Saikia D. A narrative review of anti-viral drugs used for COVID-19 pharmacotherapy. J Pharm Bioall Sci. 2021;13:163–71.

Bian L, Gao F, Zhang J, He Q, Mao Q, Xu M, Liang Z. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021;20:365–73.

Vaccines – COVID19 Vaccine Tracker [Internet]. Vaccines – COVID19 Vaccine Tracker. covid19.trackvaccines.org; [cited 2022 Mar 10]. Available from: https://covid19.trackvaccines.org/vaccines/

Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, Macdonald B, Beltekian D, Roser M. Coronavirus (COVID-19) Vaccinations - Our World in Data [Internet]. Our World in Data. ourworldindata.org; [cited 2022 Mar 11]. Available from: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL.

Krause PR, Gruber MF. Emergency use authorization of Covid vaccines - safety and efficacy follow-up considerations. N Engl J Med. 2020;383: e107. https://doi.org/10.1056/NEJMp2031373 (Epub 2020 Oct 16 PMID: 33064383).

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.

Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398:2173–84. https://doi.org/10.1016/S0140-6736(21)02000-6.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577.

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, ENSEMBLE study group, et al. Final analysis of efficacy and safety of single-dose Ad26COV2S. N Engl J Med. 2022;386(9):847–60. https://doi.org/10.1056/NEJMoa2117608.

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385:1172–83. https://doi.org/10.1056/NEJMoa2107659.

Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386:531–43. https://doi.org/10.1056/NEJMoa2116185.

El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385:1774–85. https://doi.org/10.1056/NEJMoa2113017.

Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 Infection in adults: a randomized clinical trial. JAMA. 2021;326:35–45. https://doi.org/10.1001/jama.2021.8565.

Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;385:2348–60. https://doi.org/10.1056/NEJMoa2105290.

Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2022;2021(398):213–22. https://doi.org/10.1016/S0140-6736(21)01429-X.

Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine. 2021;39:6520–8. https://doi.org/10.1016/j.vaccine.2021.09.052.

Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;2022(399):237–48. https://doi.org/10.1016/S0140-6736(21)02753-7.

Bravo L, Smolenov I, Han HH, Li P, Hosain R, Rockhold F, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022;399:461–72. https://doi.org/10.1016/S0140-6736(22)00055-1.

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;2021(397):671–81. https://doi.org/10.1016/S0140-6736(21)00234-8.

Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, ZF2001 Global trial group, et al. Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults. N Engl J Med. 2022;386(22):2097–111. https://doi.org/10.1056/NEJMoa2202261.

Khairullin B, Zakarya K, Orynbayev M, Abduraimov Y, Kassenov M, Sarsenbayeva G, et al. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: a multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. EClinicalMedicine. 2022;25(50): 101526. https://doi.org/10.1016/j.eclinm.2022.101526.

Hager KJ, Pérez Marc G, Gobeil P, Diaz RS, Heizer G, Llapur C, CoVLP study team, et al. Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine. N Engl J Med. 2022;386(22):2084–96. https://doi.org/10.1056/NEJMoa2201300.

Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, HERALD study group, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2022;22(3):329–40. https://doi.org/10.1016/S1473-3099(21)00677-0.

Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252–60.

Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12:103–11. https://doi.org/10.1007/s11739-016-1583-7.

Korang SK, von Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F, Juul S, Nielsen EE, Feinberg JB, Petersen JJ, Legart C, Kokogho A, Maagaard M, Klingenberg S, Thabane L, Bardach A, Ciapponi A, Thomsen AR, Jakobsen JC, Gluud C. Vaccines to prevent COVID-19: a living systematic review with trial sequential analysis and network meta-analysis of randomized clinical trials. PLoS ONE. 2022;17: e0260733.

Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11:22777.